Headlines about TESARO (NASDAQ:TSRO) have trended somewhat positive this week, Accern reports. The research firm scores the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. TESARO earned a news impact score of 0.25 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.1003649852039 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the media stories that may have effected Accern’s scoring:
- Stock Watch Evaluation: Tesaro Inc (NASDAQ: TSRO) – Alpha Beta Stock (alphabetastock.com)
- ETFs with exposure to TESARO, Inc. : November 13, 2017 (finance.yahoo.com)
- TESARO, Inc. (TSRO) Receives Consensus Rating of “Hold” from Brokerages (americanbankingnews.com)
- Equities Analysts Issue Forecasts for TESARO, Inc.’s FY2017 Earnings (TSRO) (americanbankingnews.com)
- TESARO, Inc. (TSRO) Earns Buy Rating from SunTrust Banks, Inc. (americanbankingnews.com)
A number of equities analysts have recently commented on the stock. Robert W. Baird reaffirmed a “neutral” rating and set a $140.00 target price (down from $155.00) on shares of TESARO in a research report on Thursday, August 10th. SunTrust Banks, Inc. reaffirmed a “buy” rating and set a $160.00 target price on shares of TESARO in a research report on Friday. Lake Street Capital reaffirmed a “buy” rating and set a $143.00 target price on shares of TESARO in a research report on Thursday, November 9th. Zacks Investment Research raised shares of TESARO from a “sell” rating to a “hold” rating in a research report on Wednesday, November 8th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of TESARO in a research report on Wednesday, November 8th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. TESARO has an average rating of “Hold” and a consensus price target of $161.72.
Shares of TESARO (NASDAQ:TSRO) traded down $5.15 on Tuesday, reaching $85.30. 1,042,436 shares of the company’s stock traded hands, compared to its average volume of 1,029,013. TESARO has a 52 week low of $88.10 and a 52 week high of $192.94. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.73 and a quick ratio of 4.35.
TESARO (NASDAQ:TSRO) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.16) by $0.69. The company had revenue of $142.77 million during the quarter, compared to the consensus estimate of $130.57 million. TESARO had a negative net margin of 251.22% and a negative return on equity of 93.39%. TESARO’s revenue was up 740.3% compared to the same quarter last year. During the same period last year, the firm earned ($1.72) earnings per share. equities analysts predict that TESARO will post -8.18 earnings per share for the current fiscal year.
In related news, Director James O. Armitage sold 10,000 shares of the firm’s stock in a transaction on Monday, September 18th. The shares were sold at an average price of $117.13, for a total transaction of $1,171,300.00. Following the completion of the transaction, the director now owns 10,000 shares of the company’s stock, valued at $1,171,300. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Edward C. English sold 10,862 shares of the firm’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $134.92, for a total transaction of $1,465,501.04. Following the transaction, the vice president now directly owns 6,258 shares of the company’s stock, valued at approximately $844,329.36. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 35,692 shares of company stock valued at $4,628,976. 34.60% of the stock is owned by insiders.
COPYRIGHT VIOLATION WARNING: This story was first reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://www.chaffeybreeze.com/2017/11/14/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-tesaro-tsro-share-price.html.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.